KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Amortization of Deferred Charges (2016 - 2021)

Jazz Pharmaceuticals has reported Amortization of Deferred Charges over the past 11 years, most recently at $15.7 million for Q1 2021.

  • Quarterly results put Amortization of Deferred Charges at $15.7 million for Q1 2021, up 30.73% from a year ago — trailing twelve months through Mar 2021 was $60.3 million (up 27.68% YoY), and the annual figure for FY2020 was $56.7 million, up 22.12%.
  • Amortization of Deferred Charges for Q1 2021 was $15.7 million at Jazz Pharmaceuticals, down from $16.0 million in the prior quarter.
  • Over the last five years, Amortization of Deferred Charges for JAZZ hit a ceiling of $16.0 million in Q4 2020 and a floor of $5.6 million in Q1 2017.
  • Median Amortization of Deferred Charges over the past 5 years was $11.3 million (2018), compared with a mean of $11.3 million.
  • Peak annual rise in Amortization of Deferred Charges hit 89.08% in 2018, while the deepest fall reached 4.62% in 2018.
  • Jazz Pharmaceuticals' Amortization of Deferred Charges stood at $10.8 million in 2017, then grew by 4.62% to $11.3 million in 2018, then rose by 6.11% to $12.0 million in 2019, then skyrocketed by 33.93% to $16.0 million in 2020, then decreased by 2.23% to $15.7 million in 2021.
  • The last three reported values for Amortization of Deferred Charges were $15.7 million (Q1 2021), $16.0 million (Q4 2020), and $15.8 million (Q3 2020) per Business Quant data.